Jolly v. Eli Lilly & Co.

751 P.2d 923, 44 Cal. 3d 1103, 245 Cal. Rptr. 658, 1988 Cal. LEXIS 86
CourtCalifornia Supreme Court
DecidedApril 7, 1988
DocketS.F. 25045
StatusPublished
Cited by616 cases

This text of 751 P.2d 923 (Jolly v. Eli Lilly & Co.) is published on Counsel Stack Legal Research, covering California Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jolly v. Eli Lilly & Co., 751 P.2d 923, 44 Cal. 3d 1103, 245 Cal. Rptr. 658, 1988 Cal. LEXIS 86 (Cal. 1988).

Opinion

Opinion

PANELLI, J.

This case presents the following questions: whether a plaintiff, in a suit for personal injury caused by a defective drug, who is unaware of any specific facts establishing wrongful conduct on the part of any drug manufacturer, may delay bringing an action until she discovers such facts; whether a claim, otherwise barred by the statute of limitations, can be revived due to our decision in Sindell v. Abbott Laboratories (1980) 26 Cal.3d 588 [163 Cal.Rptr. 132, 607 P.2d 924, 2 A.L.R.4th 1061], in which we held that a plaintiff who is unable to identify the particular manufacturer of a fungible drug that caused injury to her can state a claim by joining defendants who manufactured a substantial percentage of the market share of the allegedly defective drug; and whether the filing of the class action in Sindell, supra, tolled the statute of limitations for members of the putative class until the class was denied certification. We answer these questions in the negative and so conclude that the suit is time-barred.

I. Facts

Plaintiff Jolly was bom in 1951. In 1972, she first learned that while she was in útero her mother had ingested the synthetic drag estrogen diethylstilbestrol (DES) for the prevention of miscarriage. Plaintiff was told in 1972 that DES daughters could suffer injuries. Therefore, she went to a DES clinic at the UCLA Medical Center for a checkup. She was diagnosed as having adenosis, a precancerous condition that required careful monitoring. In 1976, she had an abnormal pap smear and underwent a dilation and curettage, a surgical procedure to remove abnormal tissue. In 1978, plaintiff underwent a complete hysterectomy and a partial vaginectomy in order to remove malignancy. As of 1972, plaintiff was aware, or at least suspected, that her condition was a result of her mother’s ingestion of DES during pregnancy.

Starting in 1972, plaintiff attempted to discover the manufacturer of the DES ingested by her mother. Efforts were increased in 1976 and 1978 when plaintiff’s condition became acute. Unfortunately, the doctor who *1108 prescribed the drug had died, 1 and plaintiff was unable to locate his records. Although the dispensing pharmacist did remember filling the DES prescription, he did not recall or have records pertaining to the specific brand used. This was not unusual since DES was a fungible drug, that is, hundreds of pharmaceutical companies made DES from a single agreed formula. The hospital where plaintiff was born was of no assistance because plaintiff’s mother did not use DES while there.

At least as of 1978, plaintiff was aware of the pendency of one or more DES suits alleging that DES manufacturers were liable to those injured due to their failure to test or failure to warn. Although she believed that DES had caused her injuries and that those who marketed DES had wrongfully marketed a defective product, there is no conclusive evidence in the record to show that a reasonable investigation by plaintiff in 1978 would have disclosed specific proven facts that would establish any wrongful conduct on the part of a DES drug manufacturer. In fact, even today defendants allege that DES is not defective, but for purposes of summary judgment have admitted the allegation of some defectiveness.

Further, plaintiff believed that she had no cause of action if she could not identify the particular manufacturer of the drug her mother took during pregnancy. Because her efforts to identify that manufacturer were unsuccessful, plaintiff did not file suit.

In March 1980, we decided Sindell v. Abbott Laboratories, supra, 26 Cal.3d 588, and held that if a plaintiff could not identify the precise drug manufacturer of the ingested DES, she could state a cause of action against the DES manufacturers of a substantial percentage of the market share of the drug. Defendants would be liable, assuming the remaining material allegations in the complaint were proven, unless they could disprove their involvement. Almost one year after Sindell, plaintiff Jolly brought this action.

Defendants moved for summary judgment, asserting that the action was barred by Code of Civil Procedure section 340, subdivision (3), 2 setting forth a one-year statute of limitations period for an action “for injury . . . caused by the wrongful act or neglect of another.” Although conceding the applicability of the one-year statutory period, plaintiff denied that the suit was time-barred. She asserted that the statute did not commence until she *1109 learned of the Sindell decision, because only then did she realize that she would be able to successfully bring her claim.

Plaintiff maintained that Sindell created a new cause of action by redefining “causation.” Prior to Sindell, she claimed, only the specific manufacturer of the pills that were ingested was deemed to have “caused” the injury. After Sindell, according to plaintiff, it was the generic drug DES that “caused” the harm, and therefore all DES manufacturers were tortfeasors.

The trial court granted defendants’ motion and entered judgment in their favor. The Court of Appeal reversed, relying on its earlier decision in Kensinger v. Abbott Laboratories (1985) 171 Cal.App.3d 376 [217 Cal.Rptr. 313]. The Court of Appeal did not address Jolly’s main argument, that the statute could not begin to run until after our decision in Sindell, supra, 26 Cal.3d 588, except by way of a footnote declining to adopt her position. 3 We granted defendants Eli Lilly and Company, Rexall Drug Company, and E.R. Squibb and Sons, Inc.’s subsequent petition for review.

II. The Kensinger Decision

As previously noted, both sides agree that the one-year limitations period of section 340, subdivision (3) applies to this case. Both sides also agree that the common law rule, that an action accrues on the date of injury (Lambert v. McKenzie (1901) 135 Cal. 100, 103 [67 P. 6]), applies only as modified by the “discovery rule.” The discovery rule provides that the accrual date of a cause of action is delayed until the plaintiff is aware of her injury and its negligent cause. 4 (Sanchez v. South Hoover Hospital, supra, 18 Cal.3d 93, 99.) A plaintiff is held to her actual knowledge as well as knowledge that could reasonably be discovered through investigation of sources open to her. (Id. at p. 101.) The parties differ as to what constitutes sufficient knowledge to start the statute running.

The Court of Appeal applied Kensinger, supra, 171 Cal.App.3d 376, a factually similar case, and found that it was a question of fact as to whether *1110

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Fierro v. Landry's Restaurant Inc.
California Court of Appeal, 2018
Batze v. Safeway, Inc.
California Court of Appeal, 2017
ZF Micro Devices v. TAT Capital Partners
California Court of Appeal, 2016
Eidson v. Medtronic, Inc.
981 F. Supp. 2d 868 (N.D. California, 2013)
City of Fresno v. Chevron U.S.A., Inc.
980 F. Supp. 2d 425 (S.D. New York, 2013)
DC Comics v. Pacific Pictures Corp.
938 F. Supp. 2d 941 (N.D. California, 2013)
Erickson v. Boston Scientific Corp.
846 F. Supp. 2d 1085 (C.D. California, 2011)
Garber v. City of Clovis
698 F. Supp. 2d 1204 (E.D. California, 2010)
Clarke v. Upton
703 F. Supp. 2d 1037 (E.D. California, 2010)
State Compensation Insurance Fund v. Superior Court
184 Cal. App. 4th 1124 (California Court of Appeal, 2010)
McCoy v. Gustafson
180 Cal. App. 4th 56 (California Court of Appeal, 2009)
In Re Methyl Tertiary Butyl Ether Liability
676 F. Supp. 2d 139 (S.D. New York, 2009)
Orange County Water District v. Unocal
676 F. Supp. 2d 139 (S.D. New York, 2009)
Raytheon Co. v. INDIGO SYSTEMS CORP.
653 F. Supp. 2d 677 (E.D. Texas, 2009)
Aguilera v. Heiman
174 Cal. App. 4th 590 (California Court of Appeal, 2009)
Schutte & Koerting, Inc. v. Swett & Crawford
298 F. App'x 613 (Ninth Circuit, 2008)
Harlow v. County of Riverside
295 F. App'x 252 (Ninth Circuit, 2008)
Henderson v. Pfizer, Inc.
285 F. App'x 370 (Ninth Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
751 P.2d 923, 44 Cal. 3d 1103, 245 Cal. Rptr. 658, 1988 Cal. LEXIS 86, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jolly-v-eli-lilly-co-cal-1988.